Skip to main content
Opthea Ltd logo

Opthea Ltd — Investor Relations & Filings

Ticker · OPT ISIN · US68386J2087 LEI · 549300Q5FMFDLP46SF83 ASX Manufacturing
Open in API
Filings indexed 1,390 across all filing types
Latest filing 2012-06-04 Regulatory Filings
Country AU Australia
Listing ASX OPT

About Opthea Ltd

https://opthea.com/

Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies for vision-threatening retinal diseases, particularly wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company's lead product candidate, sozinibercept, is a first-in-class biologic 'trap' inhibitor targeting Vascular Endothelial Growth Factors C and D (VEGF-C and VEGF-D). Sozinibercept is being developed for administration in combination with standard-of-care anti-VEGF-A therapies. This dual-pathway inhibition aims to deliver superior visual outcomes by more comprehensively blocking the mechanisms that contribute to disease progression, addressing the limitations of current treatments that only target VEGF-A. The therapy is being evaluated in late-stage pivotal clinical trials for wet AMD.

Recent filings

Filing Released Lang Actions
Trading Halt 1 page 33.6KB
Regulatory Filings Classification · 95% confidence The document is a market release announcing a trading halt for Circadian Technologies Limited securities pending a forthcoming announcement. It does not contain financial data, report content, or detailed information about company performance or management changes. It is a regulatory announcement related to trading status rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2012-06-04 English
Request for Trading Halt 2 pages 25.3KB
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to the Australian Stock Exchange requesting a trading halt for Circadian Technologies Limited shares. It references Listing Rule 17.1 and states the halt is pending an announcement regarding a proposed capital raising. The document does not contain financial data, results, or detailed report content but is an announcement related to capital market activity. This fits the category of Capital/Financing Update (CAP) as it concerns a capital raising event and trading halt related to it.
2012-06-04 English
Updated Corporate Presentation 42 pages 1.5MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation from Circadian Technologies Limited dated May 2012. It includes extensive information about the company's products, clinical trials, market opportunities, financial summaries, shareholder base, and development milestones. The content is structured as a presentation with slides, including forward-looking statements, product pipelines, market analysis, and financial highlights. There is no indication that this is an official annual or interim report, audit report, or earnings release. Instead, it is a comprehensive investor-focused presentation detailing strategy, financials, and clinical development. This matches the definition of an Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2012-05-31 English
Appendix 3B 7 pages 117.0KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and references ASX rules related to new securities issuance and quotation. It details the class, number, terms, and purpose of securities issued, including Conditional Performance Rights and options. The document is a formal announcement to the Australian Securities Exchange (ASX) about the issuance and quotation of new securities. It does not contain financial statements, management discussion, or audit information, but rather focuses on the issuance and listing of new securities. This matches the definition of a Share Issue/Capital Change announcement (SHA). The document length is over 10,000 characters, indicating it is a full announcement rather than a brief notice or report publication announcement.
2012-05-15 English
Ceasing to be a substantial holder 2 pages 44.6KB
Regulatory Filings
2012-04-25 English
Change of Director`s Interest Notice 2 pages 27.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details the change in a director's relevant interests in securities, including the nature of the indirect interest, number of securities held before and after the change, and the nature of the change (off-market transfer). This is a report of personal share transactions by a company director. The document length is 3441 characters, which is consistent with a detailed director's dealing notice. Therefore, the document fits the definition of 'Director's Dealing' (DIRS).
2012-04-01 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.